Antifungal therapy and management of complications of cryptococcosis due to Cryptococcus gattii

Clinical Infectious Diseases

Volumn 57, Issue 4, 2013, Pages 543-551

  Chen, Sharon C A ^a,e   Korman, Tony M ^b   Slavin, Monica A ^c   Marriott, Deborah ^d   Byth, Karen ^e   Bak, Narin ^f   Currie, Bart J ^g   Hajkowicz, Krispin ^g   Heath, Christopher H ^h   Kidd, Sarah ⁱ   McBride, William J H ^j   Meyer, Wieland ^a,k   Murray, Ronan ^l   Playford, E Geoffrey ^m   Sorrell, Tania C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e WESTMEAD HOSPITAL   (Australia)

^f ROYAL ADELAIDE HOSPITAL   (Australia)

^g ROYAL DARWIN HOSPITAL   (Australia)

^h UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

ⁱ WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^j JAMES COOK UNIVERSITY   (Australia)

^k WESTMEAD HOSPITAL   (Australia)

^l SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^m UNIVERSITY OF QUEENSLAND   (Australia)

more..

Author keywords

Antifungal therapy; Cryptococcus gattii; IRIS; Neurologic complications

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; GAMMA INTERFERON; POSACONAZOLE; VORICONAZOLE;

ANTIMICROBIAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID PRESSURE; CREATININE CLEARANCE; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; ERADICATION THERAPY; FEMALE; HUMAN; HYDROCEPHALUS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INTRACRANIAL PRESSURE; LUNG INFECTION; LUNG LOBECTOMY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION;

ANTIFUNGAL THERAPY; CRYPTOCOCCUS GATTII; IRIS; NEUROLOGIC COMPLICATIONS;

ADULT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; AUSTRALIA; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; FEMALE; FLUCONAZOLE; FLUCYTOSINE; FOLLOW-UP STUDIES; HUMANS; MALE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84880933473     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit341     Document Type: Article

References (30)

1. Sorrell TC, Chen SC-A, Marr KA, Phillips P. Cryptococcus gattii infection, features that distinguish infection from C. neoformans. In: Heitman J, Kozel T, Kwon Chung KJ, Perfect J, Casadevall A, et al., eds. Cryptococcus: from human pathogen to model yeast. Washington, DC: ASM Press, 2011.
2. Speed B, Dunt D. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis 1995; 21:28-34.
3. Chen SC-A, Slavin MA, Heath CH, et al. Clinical manifestations of Cryptococcus gattii infection: determinants of neurological sequelae and death. Clin Infect Dis 2012; 55:789-98.
4. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010; 50:291-322.
5. Chen S, Sorrell T, Nimmo G, et al. Epidemiology and host-and varietydependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Clin Infect Dis 2000; 31:499-508.
6. Mitchell DH, Sorrell TC, Allworth AM, et al. Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. Clin Infect Dis 1995; 20:611-6.
7. Jenny A, Pandithage K, Fisher DA, Currie BJ. Cryptococcus infection in tropical Australia. J Clin Microbiol 2004; 42:3865-8.
8. Dromer F, Mathoulin-Pelissier S, Launay O, Lortholary O, and the French Cryptococcosis Study Group. Determinants of disease presentation and outcome during cryptococcosis: the Crypto A/D Study. PLoS Med 2007; 4:e21.
9. Pappas PG, Perfect JR, Cloud GA, et al. Cryptococcus in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 2001; 33: 90-9.
10. Robertson J, Meier M, Wall J, Ying J, Fichtenbaum CJ. Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis 2006; 42:1639-46.
11. Lortholary O, Fontanet A, Mémain N, Martin A, Sitbon K, Dromer F, and the French Cryptococcosis Study Group. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HI Vassociated cryptococcosis in France. AIDS 2005; 19:1043-9.
12. Galanis E, Hoang L, Kibsey P, Morshed M, Phillips P. Clinical presentation, diagnosis and management of Cryptococcus gattii cases: lessons learned from British Columbia. Can J Dis Med Microbiol 2009; 20:23-8.
13. Mitchell DH, Sorrell TC. Pancoast's syndrome due to pulmonary infection with Cryptococcus neoformans variety gattii. Clin Infect Dis 1992; 14:1142-4.
14. Garrett L, Marr K, West S, Allada G. 74-year-old man from the Pacific Northwest with fever and a lung mass. Chest 2011; 140:814-7.
15. Kontoyiannis DP, Peitsch WK, Reddy BT, et al. Cryptococcosis in patients with cancer. Clin Infect Dis 2001; 32:e145-50.
16. Singh N, Dromer F, Perfect JR, Lortholary O. Cryptococcosis in solid organ transplant recipients: current state of the science. Clin Infect Dis 2009; 47:1321-7.
17. Fisher D, Lo D, Burrow J, Currie B. Cryptococcus neoformans in tropical northern Australia: predominantly variant gattii with good outcomes. Aust NZ J Med 1993; 23: 678-81.
18. Bicanic T, Wood R, Meintjes G, et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HI Vinfected patients: a randomized trial. Clin Infect Dis 2008; 47: 123-30.
19. Chau TT, Mai NH, Phu NH, et al. A prospective descriptive study of cryptococcal meningitis in HIV uninfected patients in Vietnam-high prevalence of Cryptococcus neoformans var. grubii in the absence of underlying disease. BMC Infect Dis 2010; 10:199.
20. Harris JR, Lockhart SR, Debess E, et al. Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. Clin Infect Dis 2011; 53:1188-98.
21. Trilles L, Fernandez-Torres B, Lazera M, Wanke B, Guarro J. In vitro antifungal susceptibility of Cryptococcus gattii. J Clin Microbiol 2004; 42: 4815-7.
22. Lockhart S, Iqbal N, Bolden C, et al. Epidemiological cutoff values for triazole drugs in Cryptococcus gattii: correlation of molecular type and in vitro susceptibility. Diagn Microbiol Infect Dis 2012; 73:144-8.
23. Bicanic T, Brouwer AE, Meintjes G, et al. Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar puncture. AIDS 2009; 23: 701-6.
24. Lalloo D, Fisher D, Naraqi S, et al. Cryptococcal meningitis (C. neoformans var. gattii) leading to blindness in previously-healthy Melanesian adults in Papua New Guinea. Q J Med 1994; 87: 343-9.
25. Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin. Infect Dis 2000; 30:c47-54.
26. Phillips P, Chapman K, Sharp M, et al. Dexamethasone in Cryptococcus gattii central nervous system infection. Clin Infect Dis 2009; 49:591.
27. Lane M, McBride J, Archer J. Steroid responsive late deterioration in Cryptococcus neoformans variety gattii meningitis. Neurology 2004; 63:713.
28. Einsiedel L, Gordon DL, Dyer JR. Paradoxical inflammatory reaction during treatment of Cryptococcus neoformans var. gattii meningitis in an HIV-seronegative woman. Clin Infect Dis 2004; 39: e78-82.
29. Boulware DR, Bonham SC, Meya DB, et al. Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. J Infect Dis 2010; 202:962-70.
30. Wiesner DL, Boulware DR. Cryptococcus-related immune reconstitution inflammatory syndrome (IRIS): pathogenesis and its clinical implications. Curr Fungal Infect Rep 2011; 5:252-61.